Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
26 August, 2025
Welcome to new TROG committee members and thank you to long-serving members
LATEST NEWS: 26 August 2025 The TROG Scientific Committee
12 August, 2025
TROG 15.03/ANZUP 16001 FASTRACK II: economic analysis shows new technique is cheaper and more effective in the Australian setting
TRIAL UPDATE: 12 August 2025 Treating inoperable kidney cancer